Krystal Biotech Inc

KRYS

Company Profile

  • Business description

    Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

  • Contact

    2100 Wharton Street
    Suite 701
    PittsburghPA15203
    USA

    T: +1 412 586-5830

    E: [email protected]

    https://www.krystalbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    295

Stocks News & Analysis

stocks

Lower production and higher prices for ASX hydrocarbon play

Improving pricing offsets severe weather impact on sales volumes.
stocks

Alphabet returns on AI investments accelerating

AI propels business across aegments, cloud is grightest; Increasing our fair value.
stocks

We lift our fair value estimate for this ASX energy play

Strong oil and LNG prices are a major win, though we don’t think they will stay high in the long term.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,887.6017.100.19%
CAC 407,980.8191.32-1.13%
DAX 4023,869.0785.49-0.36%
Dow JONES (US)48,861.81280.12-0.57%
FTSE 10010,232.2519.140.19%
HKSE25,770.67341.17-1.31%
NASDAQ24,673.249.440.04%
Nikkei 22559,284.92632.54-1.06%
NZX 50 Index12,903.31133.011.04%
S&P 5007,135.952.85-0.04%
S&P/ASX 2008,665.8025.600.30%
SSE Composite Index4,112.164.650.11%

Market Movers